Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-21

Clinical Trial Update: Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating two doses of tiotropium Respimat versus placebo in children with severe persistent asthma, reporting efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tiotropium Respimat (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2015-12-21